Navigation Links
SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM)
Date:4/8/2009

HOUSTON, April 8 /PRNewswire/ -- LaserGen, Inc., a DNA sequencing technology company, announced a definitive agreement in which SeqWright Inc. will make an equity investment in the company. Prompting its decision was LaserGen's recently revealed plans to commercialize its novel reversible terminator chemistry, Lightning Terminators(TM), for next-generation sequencing applications. The company anticipates bringing its chemistry as reagent kits to the market as early as 2010, by forming strategic partnerships with existing next-generation instrument manufacturers. SeqWright's investment and next-generation sequencing expertise are expected to facilitate LaserGen's effort in achieving that goal. Financial terms of the transaction were not disclosed.

The superior kinetics and natural DNA restoration of Lightning Terminators(TM) inform the promise of increased speed, throughput, and read-length, while lowering cost. These benefits are achieved through LaserGen's nucleotide chemistry by attaching a special terminating group directly to the base, freeing up the critical 3'-hydroxyl group. These Lightning Terminators(TM) exhibit excellent enzymatic properties with commercially available DNA polymerases. In kinetic terms, Lightning Terminators(TM) are more efficient than natural nucleotides, a measure of how fast they are added by and how well they bind to DNA polymerase. Simply stated, Lightning Terminators(TM) are better than nature. All reversible terminators required a cleavage step to remove the terminating and fluorescent dye groups. Upon cleavage, however, Lightning Terminators(TM) restore the incorporated nucleotide back to its natural state. This distinguishes the LaserGen chemistry from other reversible terminators, which leave accumulating molecular scars as the DNA strand propagates.

The decision to invest in LaserGen represents SeqWright's ongoing initiative to support the development of and build upon its previous investments in next-generation sequencing technologies. As a large-scale provider of DNA sequencing services, SeqWright is ideally suited to invest in next-generation technologies by providing equity investment, testing and validation. "We are very pleased to support LaserGen in their efforts," says Dr. Fei Lu, M.D., CEO of SeqWright Inc., "to advance the state of DNA sequencing, and we are excited about the savings in both, time and cost, which we expect their technologies to generate."

About LaserGen

LaserGen, Inc. is an early-stage nucleic acids chemistry company, founded in 2002. The company has been funded through NIH-sponsored small business and research grants to develop a variety of innovative technologies for next-generation sequencing applications. The SeqWright agreement marks LaserGen's transition from bench discoveries to market-ready technologies. Information about LaserGen, Inc. is available at www.lasergen.com

About SeqWright

SeqWright Inc. is a commercial provider of genomic analysis and molecular biology services. SeqWright has more than 15 years of experience specializing in state-of-the-art molecular biology and genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright, please visit www.seqwright.com.


'/>"/>
SOURCE SeqWright Inc.; LaserGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. California Grants SeqWright License to Operate as a Clinical Laboratory
2. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
3. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
4. Voler Systems Continues Investments and Expands Services
5. Pharmaxis Investor Conference Call
6. Senetek PLC Announces New Investor Communication Hotline
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Stallergenes : Investor Meeting: Webcast is Available
11. Accera, Inc. to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):